Literature DB >> 9496151

Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis.

C P Simeon1, L Armadans, V Fonollosa, M Vilardell, J Candell, C Tolosa, F Mearin, M J Rodrigo, R Solans, J Lima, G Sampol.   

Abstract

OBJECTIVE: To identify survival prognostic factors and markers of morbidity among patients with systemic sclerosis (SSc). PATIENTS AND METHODS: The study included 72 patients diagnosed with SSc. According to the extent of skin involvement, three groups of patients were established: group 1, without sclerosis and with sclerosis of fingers and neck; group 2, with sclerosis of face and distal to elbows and knees; group 3, with generalised sclerosis including the trunk. All patients were included in a study protocol to determine visceral involvement. Cumulative survival after first symptom has been estimated according to the Kaplan-Meier method. The association between a hypothetical prognostic factor and cumulative survival after first symptom was assessed by log rank test. The association between a hypothetical risk factor and the prevalence of severe morbidity was assessed by the odds ratio. Multiple logistic regression models were used to identify the main predictors of severe morbidity.
RESULTS: Survival was estimated to be 85% 10 years after first SSc symptom. Survival was higher among SSc patients with skin involvement distal to elbows and knees than among the rest of patients; a forced vital capacity (FVC) on spirometry lower than 70% of expected value was associated with a shorter survival, even after adjustment for diffuse SSc. Skin involvement proximal to elbows or knees was associated with a higher prevalence of severe morbidity (OR = 46.57; p < 0.001). According to a multiple logistic regression, severe morbidity was higher among patients with skin involvement proximal to knees or elbows (OR = 40.92; p < 0.001) or among patients with pulmonary hypertension detected by Doppler echocardiography (OR = 23.66 p < 0.001).
CONCLUSIONS: In patients with SSc the extent of skin sclerosis was found to be a determining factor on the prognosis. According to skin sclerosis extent two main subsets of SSc patients with different survival incidence and degree of morbidity could be clearly established: limited SSc, formed by patients with no skin sclerosis or with sclerosis distal to elbows and knees and diffuse SSc, formed by patients with skin sclerosis distal and proximal to elbows and knees. Moreover, lung involvement (FVC < 70% on survival study and pulmonary hypertension on morbidity study) was an important and independent prognostic factor.

Entities:  

Mesh:

Year:  1997        PMID: 9496151      PMCID: PMC1752304          DOI: 10.1136/ard.56.12.723

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  21 in total

Review 1.  Scleroderma and survival.

Authors:  A J Silman
Journal:  Ann Rheum Dis       Date:  1991-04       Impact factor: 19.103

2.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

Authors:  E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

3.  A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease.

Authors:  A J Barnett; M H Miller; G O Littlejohn
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

4.  Survival in scleroderma.

Authors:  R Bennett; R Bluestone; P J Holt; E G Bywaters
Journal:  Ann Rheum Dis       Date:  1971-11       Impact factor: 19.103

Review 5.  Epidemiology and natural history of systemic sclerosis.

Authors:  V D Steen; T A Medsger
Journal:  Rheum Dis Clin North Am       Date:  1990-02       Impact factor: 2.670

6.  Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound.

Authors:  M Berger; A Haimowitz; A Van Tosh; R L Berdoff; E Goldberg
Journal:  J Am Coll Cardiol       Date:  1985-08       Impact factor: 24.094

7.  Prediction of survival in progressive systemic sclerosis by multivariate analysis of clinical features.

Authors:  J Wynn; N Fineberg; L Matzer; X Cortada; W Armstrong; J C Dillon; E L Kinney
Journal:  Am Heart J       Date:  1985-07       Impact factor: 4.749

8.  Predictors of survival in systemic sclerosis (scleroderma).

Authors:  R D Altman; T A Medsger; D A Bloch; B A Michel
Journal:  Arthritis Rheum       Date:  1991-04

9.  APACHE-acute physiology and chronic health evaluation: a physiologically based classification system.

Authors:  W A Knaus; J E Zimmerman; D P Wagner; E A Draper; D E Lawrence
Journal:  Crit Care Med       Date:  1981-08       Impact factor: 7.598

10.  Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases.

Authors:  Y M Traub; A P Shapiro; G P Rodnan; T A Medsger; R H McDonald; V D Steen; T A Osial; S F Tolchin
Journal:  Medicine (Baltimore)       Date:  1983-11       Impact factor: 1.889

View more
  15 in total

Review 1.  Bone marrow transplantation in the treatment of systemic sclerosis.

Authors:  F Viganego; R Nash; D E Furst
Journal:  Curr Rheumatol Rep       Date:  2000-12       Impact factor: 4.592

2.  Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry.

Authors:  D Farge; J Passweg; J M van Laar; Z Marjanovic; C Besenthal; J Finke; H H Peter; F C Breedveld; W E Fibbe; C Black; C Denton; I Koetter; F Locatelli; A Martini; A V N Schattenberg; F van den Hoogen; L van de Putte; F Lanza; R Arnold; P A Bacon; S Bingham; F Ciceri; B Didier; J L Diez-Martin; P Emery; W Feremans; B Hertenstein; F Hiepe; R Luosujärvi; A Leon Lara; A Marmont; A M Martinez; H Pascual Cascon; C Bocelli-Tyndall; E Gluckman; A Gratwohl; A Tyndall
Journal:  Ann Rheum Dis       Date:  2004-08       Impact factor: 19.103

Review 3.  Systemic sclerosis: a world wide global analysis.

Authors:  Paola Coral-Alvarado; Aryce L Pardo; Natalia Castaño-Rodriguez; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  Clin Rheumatol       Date:  2009-03-11       Impact factor: 2.980

4.  Effect of mycophenolate sodium in scleroderma-related interstitial lung disease.

Authors:  Carmen Pilar Simeón-Aznar; Vicent Fonollosa-Plá; Carles Tolosa-Vilella; Albert Selva-O'Callaghan; Roser Solans-Laqué; Miquel Vilardell-Tarrés
Journal:  Clin Rheumatol       Date:  2011-09-01       Impact factor: 2.980

5.  The scleroderma Assessment Questionnaire (SAQ). A new self-assessment questionnaire for evaluation of disease status in patients with systemic sclerosis.

Authors:  P Ostojić; N Damjanov
Journal:  Z Rheumatol       Date:  2006-03       Impact factor: 1.372

6.  Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele.

Authors:  P G Vlachoyiannopoulos; U G Dafni; I Pakas; M Spyropoulou-Vlachou; C Stavropoulos-Giokas; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2000-05       Impact factor: 19.103

Review 7.  Lung Transplantation in Patients With Systemic Sclerosis.

Authors:  Rupal J Shah; Francesco Boin
Journal:  Curr Rheumatol Rep       Date:  2017-05       Impact factor: 4.592

Review 8.  Interstitial lung disease in systemic sclerosis.

Authors:  Predrag Ostojic; Marco Matucci Cerinic; Richard Silver; Kristin Highland; Nemanja Damjanov
Journal:  Lung       Date:  2007 Jul-Aug       Impact factor: 2.584

9.  The prognostic factors of systemic sclerosis for survival among Koreans.

Authors:  Jinhyun Kim; Sue Kyung Park; Ki Won Moon; Eun Young Lee; Yun Jong Lee; Yeong Wook Song; Eun Bong Lee
Journal:  Clin Rheumatol       Date:  2009-12-03       Impact factor: 2.980

10.  Clinical and genetic factors predictive of mortality in early systemic sclerosis.

Authors:  Shervin Assassi; Deborah Del Junco; Kari Sutter; Terry A McNearney; John D Reveille; Andrew Karnavas; Pravitt Gourh; Rosa M Estrada-Y-Martin; Michael Fischbach; Frank C Arnett; Maureen D Mayes
Journal:  Arthritis Rheum       Date:  2009-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.